Blocking the IL-1β receptor in liver cancer cells resulted in the disappearance of differences in PKM2 expression between the two groups, and there were similar changes in glucose consumption and lactate production, which are critical indicators of glycolytic function. The gene discussed is PKM; the disease is liver cancer.